Sugi Predict

Sugi Predict / Compounds / SCHEMBL1893073

SCHEMBL1893073

SCHEMBL1893073

Cc1cc(F)c(Nc2cc(C(C)(C)C)nn2-c2ccccc2)cc1-c1nc2cnc(N)nc2n(C)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK12 P53778 9/20 0.42
▸ MAPK14 Q16539 9/20 0.42
▸ MAPK13 O15264 8/20 0.42
▸ MAPK11 Q15759 8/20 0.42
▸ BRAF P15056 4/20 0.39
▸ CYP1A2 P05177 4/20 0.39
▸ USP2 O75604 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ MEN1 O00255 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ CASP7 P55210 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ DDR2 Q16832 2/20 0.36
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ MAP3K7 O43318 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1890805 0.88 CYP1A2 (0.36) MAPK14BRAFCYP1A2USP2ALDH1A1
SCHEMBL1521892 0.82 MAPK14 (0.55) MAPK12MAPK14MAPK13MAPK11BRAF
SCHEMBL1521999 0.81 MAPK14 (0.52) MAPK12MAPK14MAPK13MAPK11BRAF
SCHEMBL1521762 0.81 BRAF (0.43) MAPK12MAPK14MAPK13MAPK11BRAF
SCHEMBL1521775 0.79 MAPK14 (0.56) MAPK12MAPK14MAPK13MAPK11BRAF
SCHEMBL1521614 0.73 CYP1A2 (0.43) CYP1A2USP2ALDH1A1MAPK1MEN1
SCHEMBL4563448 0.73 BRAF (0.49) MAPK12MAPK14MAPK13MAPK11BRAF
SCHEMBL5065309 0.71 BRAF (0.63) MAPK12MAPK14MAPK13MAPK11BRAF
SCHEMBL5065364 0.70 MAPK14 (0.53) MAPK12MAPK14MAPK13MAPK11BRAF
SCHEMBL1521998 0.70 MAPK14 (0.56) MAPK12MAPK14MAPK13MAPK11BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
EP-2063896-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 — — EP disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 MAPK12 116/4885MAPK14 240/4885MAPK13 156/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 MAPK12 116/4885MAPK14 240/4885MAPK13 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.